871038-72-1 | potassium 4-{[(4-fluorophenyl)methyl]carbamoyl}-1-methyl-2-{2-[(5-methyl-1,3,4-oxadiazol-2-yl)formamido]propan-2-yl}-6-oxo-1,6-dihydropyrimidin-5-olate

Packsize	Purity	Availability	Price	Discounted Price
5mg	98%	in stock	$11.00	$8.00
10mg	98%	in stock	$13.00	$9.00
25mg	98%	in stock	$16.00	$11.00
1g	98%	in stock	$20.00	$14.00
5g	98%	in stock	$54.00	$38.00
25g	98%	in stock	$194.00	$136.00
100g	98%	in stock	$760.00	$532.00

Description

• Catalog Number: AB78799
• Chemical Name: potassium 4-{[(4-fluorophenyl)methyl]carbamoyl}-1-methyl-2-{2-[(5-methyl-1,3,4-oxadiazol-2-yl)formamido]propan-2-yl}-6-oxo-1,6-dihydropyrimidin-5-olate
• CAS Number: 871038-72-1
• Molecular Formula: C20H20FKN6O5
• Molecular Weight: 482.5067
• MDL Number: MFCD10698872
• SMILES: Fc1ccc(cc1)CNC(=O)c1nc(n(c(=O)c1[O-])C)C(NC(=O)c1nnc(o1)C)(C)C.[K+]

Computed Properties

• Complexity: 843
• Covalently-Bonded Unit Count: 2
• Heavy Atom Count: 33
• Hydrogen Bond Acceptor Count: 9
• Hydrogen Bond Donor Count: 2
• Rotatable Bond Count: 6

Literature

• Antiviral Activity of Bictegravir and Cabotegravir against Integrase Inhibitor-Resistant SIVmac239 and HIV-1.

  Antimicrobial agents and chemotherapy 20171201

• Impact of HIV-1 Integrase L74F and V75I Mutations in a Clinical Isolate on Resistance to Second-Generation Integrase Strand Transfer Inhibitors.

  Antimicrobial agents and chemotherapy 20170801

• Characterization and in vitro activity of a branched peptide boronic acid that interacts with HIV-1 RRE RNA.

  Bioorganic & medicinal chemistry 20160901

• Antiviral characteristics of GSK1265744, an HIV integrase inhibitor dosed orally or by long-acting injection.

  Antimicrobial agents and chemotherapy 20150101

• Bicyclic 1-hydroxy-2-oxo-1,2-dihydropyridine-3-carboxamide-containing HIV-1 integrase inhibitors having high antiviral potency against cells harboring raltegravir-resistant integrase mutants.

  Journal of medicinal chemistry 20140227

• Pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1-infected children aged 2 through 18 years.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20140201

• Characterization of binding of raltegravir to plasma proteins.

  Antimicrobial agents and chemotherapy 20131001

• Raltegravir flexibility and its impact on recognition by the HIV-1 IN targets.

  Journal of molecular recognition : JMR 20130901

• Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study.

  Lancet (London, England) 20130824

• Antiretroviral therapy: dolutegravir sets SAIL(ING).

  Lancet (London, England) 20130824

• Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials.

  The Lancet. Infectious diseases 20130701

• Cellular pharmacology and potency of HIV-1 nucleoside analogs in primary human macrophages.

  Antimicrobial agents and chemotherapy 20130301

• Ruthenium arene complexes as HIV-1 integrase strand transfer inhibitors.

  Journal of inorganic biochemistry 20130101

• Monitoring the emergence of resistance mutations in patients infected with HIV-1 under salvage therapy with raltegravir in Rio de Janeiro, Brazil: a follow-up study.

  Journal of medical virology 20121201

• Measurement of plasma and intracellular concentrations of raltegravir in patients with HIV infection.

  AIDS (London, England) 20121113

• A novel ultrasensitive LC-MS/MS assay for quantification of intracellular raltegravir in human cell extracts.

  Journal of pharmaceutical and biomedical analysis 20121101

• The activity of the integrase inhibitor dolutegravir against HIV-1 variants isolated from raltegravir-treated adults.

  Journal of acquired immune deficiency syndromes (1999) 20121101

• A randomized controlled trial assessing the effects of raltegravir intensification on endothelial function in treated HIV infection.

  Journal of acquired immune deficiency syndromes (1999) 20121101

• LDL subclasses and lipoprotein-phospholipase A2 activity in suppressed HIV-infected patients switching to raltegravir: Spiral substudy.

  Atherosclerosis 20121101

• A switch in therapy to a reverse transcriptase inhibitor sparing combination of lopinavir/ritonavir and raltegravir in virologically suppressed HIV-infected patients: a pilot randomized trial to assess efficacy and safety profile: the KITE study.

  AIDS research and human retroviruses 20121001

• Prevalence of HIV-1 integrase mutations related to resistance to dolutegravir in raltegravir naïve and pretreated patients.

  Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 20121001

• Risk factors for raltegravir resistance development in clinical practice.

  The Journal of antimicrobial chemotherapy 20121001

• Raltegravir-induced DRESS syndrome.

  Scandinavian journal of infectious diseases 20121001

• The effect of intensification with raltegravir on the HIV-1 reservoir of latently infected memory CD4 T cells in suppressed patients.

  AIDS (London, England) 20120924

• Long-term glucose tolerance in highly experienced HIV-infected patients receiving nucleoside analogue-sparing regimens.

  AIDS (London, England) 20120910

• Drug resistance mutations of HIV type 1 non-B viruses to integrase inhibitors in treatment-naive patients from sub-saharan countries and discordant interpretations.

  AIDS research and human retroviruses 20120901

• Sustained efficacy and safety of raltegravir after 5 years of combination antiretroviral therapy as initial treatment of HIV-1 infection: final results of a randomized, controlled, phase II study (Protocol 004).

  Journal of acquired immune deficiency syndromes (1999) 20120901

• The use of HIV-1 integrase inhibitors in antiretroviral naive patients.

  Current opinion in HIV and AIDS 20120901

• Pharmacology of HIV integrase inhibitors.

  Current opinion in HIV and AIDS 20120901

• A randomized trial of Raltegravir replacement for protease inhibitor or non-nucleoside reverse transcriptase inhibitor in HIV-infected women with lipohypertrophy.

  AIDS patient care and STDs 20120901

• HIV integrase inhibitors in ART-experienced patients.

  Current opinion in HIV and AIDS 20120901

• Tolerability of HIV integrase inhibitors.

  Current opinion in HIV and AIDS 20120901

• Synthetic approaches and pharmacological activity of 1,3,4-oxadiazoles: a review of the literature from 2000-2012.

  Molecules (Basel, Switzerland) 20120827

• Gastrointestinal-associated lymphoid tissue immune reconstitution in a randomized clinical trial of raltegravir versus non-nucleoside reverse transcriptase inhibitor-based regimens.

  AIDS (London, England) 20120824

• Short communication: lack of correlation between UGT1A1*6, *28 genotypes, and plasma raltegravir concentrations in Japanese HIV type 1-infected patients.

  AIDS research and human retroviruses 20120801

• Drug interaction profile for GSK2248761, a next generation non-nucleoside reverse transcriptase inhibitor.

  British journal of clinical pharmacology 20120801

• Pharmacokinetic and safety of raltegravir in pregnancy.

  European journal of clinical pharmacology 20120801

• Design, synthesis and antiviral activity of novel pyridazines.

  European journal of medicinal chemistry 20120801

• Understanding the effect of drug-resistant mutations of HIV-1 intasome on raltegravir action through molecular modeling study.

  Molecular bioSystems 20120801

• Testing superiority at interim analyses in a non-inferiority trial.

  Statistics in medicine 20120710

• Low frequency of skin reactions in a cohort of patients on raltegravir.

  The Journal of antimicrobial chemotherapy 20120701

• In-vivo selection of the mutation F121Y in a patient failing raltegravir containing salvage regimen.

  Antiviral research 20120701

• Update on raltegravir and the development of new integrase strand transfer inhibitors.

  Southern medical journal 20120701

• Virological failure at one year in triple-class experienced patients switching to raltegravir-based regimens is not predicted by baseline factors.

  International journal of STD & AIDS 20120701

• A randomized study of pharmacokinetics, efficacy, and safety of 2 raltegravir plus atazanavir strategies in ART-treated adults.

  Journal of acquired immune deficiency syndromes (1999) 20120601

• A highly intensified ART regimen induces long-term viral suppression and restriction of the viral reservoir in a simian AIDS model.

  PLoS pathogens 20120601

• [Undetectable viral load after the addition of raltegravir in a 36 week pregnant adolescent with high-level HIV viraemia].

  Anales de pediatria (Barcelona, Spain : 2003) 20120501

• Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals.

  Gastroenterology 20120501

• Long-term efficacy and safety of raltegravir, etravirine, and darunavir/ritonavir in treatment-experienced patients: week 96 results from the ANRS 139 TRIO trial.

  Journal of acquired immune deficiency syndromes (1999) 20120415

• [Leucoencephalopathy in a patient with type I human immunodeficiency virus (HIV-1) infection and symptoms of a hypertensive emergency].

  Enfermedades infecciosas y microbiologia clinica 20120401

• Discovery of drugs that possess activity against feline leukemia virus.

  The Journal of general virology 20120401

• Raltegravir, tenofovir DF, and emtricitabine for postexposure prophylaxis to prevent the sexual transmission of HIV: safety, tolerability, and adherence.

  Journal of acquired immune deficiency syndromes (1999) 20120401

• Hydroxyl may not be indispensable for raltegravir: Design, synthesis and SAR Studies of raltegravir derivatives as HIV-1 inhibitors.

  European journal of medicinal chemistry 20120401

• Intrapatient and interpatient pharmacokinetic variability of raltegravir in the clinical setting.

  Therapeutic drug monitoring 20120401

• Role of raltegravir in HIV-1 management.

  The Annals of pharmacotherapy 20120401

• Mechanisms involved in CD4 cell gains in HIV-infected patients switched to raltegravir.

  AIDS (London, England) 20120313

• Integrated HIV DNA accumulates prior to treatment while episomal HIV DNA records ongoing transmission afterwards.

  AIDS (London, England) 20120313

• Limited sampling strategies for the estimation of raltegravir daily exposure in HIV-infected patients.

  Journal of clinical pharmacology 20120301

• No effect of raltegravir intensification on viral replication markers in the blood of HIV-1-infected patients receiving antiretroviral therapy.

  Journal of acquired immune deficiency syndromes (1999) 20120301

• Potent and sustained antiviral response of raltegravir-based highly active antiretroviral therapy in HIV type 1-infected children and adolescents.

  The Pediatric infectious disease journal 20120301

• Homology model-guided 3D-QSAR studies of HIV-1 integrase inhibitors.

  Journal of chemical information and modeling 20120227

• Body composition changes after switching from protease inhibitors to raltegravir: SPIRAL-LIP substudy.

  AIDS (London, England) 20120220

• [Raltegravir in HIV-infected patients with high vascular risk].

  Medicina clinica 20120218

• Study of genotypic and phenotypic HIV-1 dynamics of integrase mutations during raltegravir treatment: a refined analysis by ultra-deep 454 pyrosequencing.

  The Journal of infectious diseases 20120215

• Plasma raltegravir exposure influences the antiviral activity and selection of resistance mutations.

  AIDS research and human retroviruses 20120201

• Safety and efficacy of raltegravir in patients with HIV-1 and hepatitis B and/or C virus coinfection.

  HIV medicine 20120201

• Co-administration of raltegravir reduces daily darunavir exposure in HIV-1 infected patients.

  Pharmacological research 20120201

• Bicyclic hydroxy-1H-pyrrolopyridine-trione containing HIV-1 integrase inhibitors.

  Chemical biology & drug design 20120201

• Inter- and intra-patient variability of raltegravir pharmacokinetics in HIV-1-infected subjects.

  The Journal of antimicrobial chemotherapy 20120201

• In vitro resistance selections using elvitegravir, raltegravir, and two metabolites of elvitegravir M1 and M4.

  Antiviral research 20120201

• Acceptable plasma concentrations of raltegravir and etravirine when administered by gastrostomy tube in a patient with advanced multidrug-resistant human immunodeficiency virus infection.

  Pharmacotherapy 20120201

• Effect of raltegravir intensification on HIV proviral DNA in the blood and gut mucosa of men on long-term therapy: a randomized controlled trial.

  AIDS (London, England) 20120114

• Safety and effectiveness of raltegravir in patients with haemophilia and anti-HIV multidrug resistance.

  Haemophilia : the official journal of the World Federation of Hemophilia 20120101

• Antiviral effect of raltegravir on HTLV-1 carriers.

  The Journal of antimicrobial chemotherapy 20120101

• Adherence and preexisting major protease inhibitor resistance mutations are associated with virologic failure of a dual-class antiretroviral regimen with inhibitors of HIV-1 viral protease and integrase.

  Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 20120101

• Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study.

  The Lancet. Infectious diseases 20120101

• Elvitegravir: a once daily alternative to raltegravir.

  The Lancet. Infectious diseases 20120101

• Diketoacid inhibitors of HIV-1 integrase: from L-708,906 to raltegravir and beyond.

  Current medicinal chemistry 20120101

• Immunologic effectiveness of maraviroc- and raltegravir-containing regimens (R+M+) versus raltegravir-based regimens that do not include maraviroc (R+M-).

  Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 20120101

• Pharmacokinetics of abacavir and its anabolite carbovir triphosphate without and with darunavir/ritonavir or raltegravir in HIV-infected subjects.

  Antiviral therapy 20120101

• Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week study.

  Antiviral therapy 20120101

• HIV-associated gastric natural killer/T-cell lymphoma.

  International journal of STD & AIDS 20120101

• Impaired maraviroc and raltegravir clearance in a human immunodeficiency virus-infected patient with end-stage liver disease and renal impairment: a management dilemma.

  Pharmacotherapy 20120101

• Switching virally suppressed, treatment-experienced patients to a raltegravir-containing regimen does not alter levels of HIV-1 DNA.

  PloS one 20120101

• Genetic barrier to the development of resistance to integrase inhibitors in HIV-1 subtypes CRF01_AE and B.

  Intervirology 20120101

• A nucleoside- and ritonavir-sparing regimen containing atazanavir plus raltegravir in antiretroviral treatment-naïve HIV-infected patients: SPARTAN study results.

  HIV clinical trials 20120101

• Unprocessed viral DNA could be the primary target of the HIV-1 integrase inhibitor raltegravir.

  PloS one 20120101

• 96 Week follow-up of HIV-infected patients in rescue with raltegravir plus optimized backbone regimens: a multicentre Italian experience.

  PloS one 20120101

• Efficacy of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients: week-192 overall and subgroup analyses from STARTMRK.

  HIV clinical trials 20120101

• The role of raltegravir in the treatment of HIV-2 infections: evidence from a case series.

  Antiviral therapy 20120101

• Three main mutational pathways in HIV-2 lead to high-level raltegravir and elvitegravir resistance: implications for emerging HIV-2 treatment regimens.

  PloS one 20120101

• Prolonged and substantial discordance in prevalence of raltegravir-resistant HIV-1 in plasma versus PBMC samples revealed by 454 'deep' sequencing.

  PloS one 20120101

• Elevated liver enzymes resulting from an interaction between Raltegravir and Panax ginseng: a case report and brief review.

  Drug metabolism and drug interactions 20120101

• Investigating the role of metal chelation in HIV-1 integrase strand transfer inhibitors.

  Journal of medicinal chemistry 20111222

• Plasma and intracellular pharmacokinetics of darunavir/ritonavir once daily and raltegravir once and twice daily in HIV-infected individuals.

  Journal of acquired immune deficiency syndromes (1999) 20111215

• Raltegravir treatment intensification does not alter cerebrospinal fluid HIV-1 infection or immunoactivation in subjects on suppressive therapy.

  The Journal of infectious diseases 20111215

• Autoimmune disease: A role for new anti-viral therapies?

  Autoimmunity reviews 20111201

• Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial.

  The Lancet. Infectious diseases 20111201

• The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype.

  The Journal of antimicrobial chemotherapy 20111201

• Cross-resistance profile of the novel integrase inhibitor Dolutegravir (S/GSK1349572) using clonal viral variants selected in patients failing raltegravir.

  The Journal of infectious diseases 20111201

• A sensitive liquid chromatography coupled with mass spectrometry method for the intracellular and plasma quantification of raltegravir after solid-phase extraction.

  The Journal of pharmacy and pharmacology 20111201

• Cost-effectiveness of raltegravir in HIV/AIDS.

  Expert review of pharmacoeconomics & outcomes research 20111201

• Phenotypic susceptibility of HIV-2 to raltegravir: integrase mutations Q148R and N155H confer raltegravir resistance.

  AIDS (London, England) 20111128

• Sustained virological response to a raltegravir-containing salvage therapy in an HIV-2-infected patient.

  AIDS (London, England) 20111128

• Intensification of antiretroviral therapy with raltegravir or addition of hyperimmune bovine colostrum in HIV-infected patients with suboptimal CD4+ T-cell response: a randomized controlled trial.

  The Journal of infectious diseases 20111115

• Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262).

  AIDS (London, England) 20111113

• Impact of treatment with raltegravir during primary or chronic HIV infection on RNA decay characteristics and the HIV viral reservoir.

  AIDS (London, England) 20111113

• The SnoB study: frequency of baseline raltegravir resistance mutations prevalence in different non-B subtypes.

  Medical microbiology and immunology 20111101

• MK-0536 inhibits HIV-1 integrases resistant to raltegravir.

  Antimicrobial agents and chemotherapy 20111101

• Raltegravir dosage adjustment in HIV-infected patients receiving etravirine.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20111101

• Switching between raltegravir resistance pathways analyzed by deep sequencing.

  AIDS (London, England) 20111023

• Clinical pharmacology profile of raltegravir, an HIV-1 integrase strand transfer inhibitor.

  Journal of clinical pharmacology 20111001

• Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20111001

• [Raltegravir in a special case: patient with HIV and Burkitt's lymphoma].

  Deutsche medizinische Wochenschrift (1946) 20111001

• Deep molecular characterization of HIV-1 dynamics under suppressive HAART.

  PLoS pathogens 20111001

• [Human immunodeficiency virus and Chagas disease coinfection treated successfully with benznidazole and a raltegravir-based antiretroviral regimen: a case report].

  Medicina clinica 20110910

• Efficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trial.

  The Journal of antimicrobial chemotherapy 20110901

• IL-15 delays suppression and fails to promote immune reconstitution in virally suppressed chronically SIV-infected macaques.

  Blood 20110901

• Inhibition of Feline leukemia virus replication by the integrase inhibitor Raltegravir.

  Veterinary microbiology 20110826

• DRESS syndrome associated with raltegravir.

  Dermatology online journal 20110815

• Microwave assisted organic synthesis (MAOS) of small molecules as potential HIV-1 integrase inhibitors.

  Molecules (Basel, Switzerland) 20110811

• Pharmacokinetics of the raltegravir/maraviroc/etravirine combination.

  The Journal of antimicrobial chemotherapy 20110801

• Resistance to raltegravir highlights integrase mutations at codon 148 in conferring cross-resistance to a second-generation HIV-1 integrase inhibitor.

  Antiviral research 20110801

• A randomized cross-over study to compare raltegravir and efavirenz (SWITCH-ER study).

  AIDS (London, England) 20110731

• HIV-1 integrase strand transfer inhibitors stabilize an integrase-single blunt-ended DNA complex.

  Journal of molecular biology 20110729

• Clinical efficacy of raltegravir against B and non-B subtype HIV-1 in phase III clinical studies.

  AIDS (London, England) 20110717

• Short communication: high effectiveness of etravirine in routine clinical practice in treatment-experienced HIV type 1-infected patients.

  AIDS research and human retroviruses 20110701

• Prevalence of resistance mutations related to integrase inhibitor S/GSK1349572 in HIV-1 subtype B raltegravir-naive and -treated patients.

  The Journal of antimicrobial chemotherapy 20110701

• Cell disposition of raltegravir and newer antiretrovirals in HIV-infected patients: high inter-individual variability in raltegravir cellular penetration.

  The Journal of antimicrobial chemotherapy 20110701

• Effect of continuous venovenous hemodiafiltration on darunavir and raltegravir exposure after administration via a gastroduodenal tube.

  AIDS (London, England) 20110619

• Lack of a clinically meaningful pharmacokinetic effect of rifabutin on raltegravir: in vitro/in vivo correlation.

  Journal of clinical pharmacology 20110601

• Evolution patterns of raltegravir-resistant mutations after integrase inhibitor interruption.

  Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 20110601

• Liver tolerance of raltegravir-containing antiretroviral therapy in HIV-infected patients with chronic hepatitis C.

  The Journal of antimicrobial chemotherapy 20110601

• Pharmacokinetic and safety profile of raltegravir and ribavirin, when dosed separately and together, in healthy volunteers.

  The Journal of antimicrobial chemotherapy 20110601

• Resistance associated mutations to dolutegravir (S/GSK1349572) in HIV-infected patients--impact of HIV subtypes and prior raltegravir experience.

  Antiviral research 20110601

• Elvitegravir overcomes resistance to raltegravir induced by integrase mutation Y143.

  AIDS (London, England) 20110601

• Raltegravir in pregnancy: a case series presentation.

  International journal of STD & AIDS 20110601

• [Long-term therapy strategy with raltegravir. Appropriate in all illness phases].

  MMW Fortschritte der Medizin 20110505

• Normal plasma FGF23 levels kinetic in tenofovir-related hypophosphatemic osteomalacia in an HIV-infected patient with von Recklinghausen disease.

  Joint, bone, spine : revue du rhumatisme 20110501

• Viral suppression rates in salvage treatment with raltegravir improved with the administration of genotypic partially active or inactive nucleoside/tide reverse transcriptase inhibitors.

  Journal of acquired immune deficiency syndromes (1999) 20110501

• HIV-1 integrase inhibitor resistance and its clinical implications.

  The Journal of infectious diseases 20110501

• Clinical evaluation of the determination of plasma concentrations of darunavir, etravirine, raltegravir and ritonavir in dried blood spot samples.

  Bioanalysis 20110501

• Reply to 'Pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in treatment experienced patients'.

  AIDS (London, England) 20110424

• Comparison of the influence of four classes of HIV antiretrovirals on adipogenic differentiation: the minimal effect of raltegravir and atazanavir.

  Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 20110401

• Durability and safety of a novel salvage therapy in R5-tropic HIV-infected patients: maraviroc, raltegravir, etravirine.

  Journal of acquired immune deficiency syndromes (1999) 20110401

• Potential of novel antiretrovirals to modulate expression and function of drug transporters in vitro.

  The Journal of antimicrobial chemotherapy 20110401

• Pharmacokinetics and safety of the co-administration of the antiretroviral raltegravir and the lipid-lowering drug ezetimibe in healthy volunteers.

  The Journal of antimicrobial chemotherapy 20110401

• Effect of raltegravir on estradiol and norgestimate plasma pharmacokinetics following oral contraceptive administration in healthy women.

  British journal of clinical pharmacology 20110401

• A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response.

  The Journal of infectious diseases 20110401

• Neutral actions of Raltegravir on adipogenesis, glucose metabolism and lipolysis in 3T3-L1 adipocytes.

  Current HIV research 20110401

• Emerging integrase inhibitor resistance mutations in raltegravir-treated HIV-1-infected patients with low-level viremia.

  AIDS (London, England) 20110313

• Severe insomnia related to high concentrations of raltegravir.

  AIDS (London, England) 20110313

• Effect of low-, moderate-, and high-fat meals on raltegravir pharmacokinetics.

  Journal of clinical pharmacology 20110301

• Darunavir/ritonavir and raltegravir coadministered in routine clinical practice: potential role for an unexpected drug interaction.

  Pharmacological research 20110301

• Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens.

  The Annals of pharmacotherapy 20110301

• Raltegravir: the first HIV-1 integrase strand transfer inhibitor in the HIV armamentarium.

  Annals of the New York Academy of Sciences 20110301

• Long-term successful control of super-multidrug-resistant human immunodeficiency virus type 1 infection by a novel combination therapy of raltegravir, etravirine, and boosted-darunavir.

  Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 20110201

• In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor.

  Antimicrobial agents and chemotherapy 20110201

• HIV-1 integrase strand-transfer inhibitors: design, synthesis and molecular modeling investigation.

  European journal of medicinal chemistry 20110201

• Simultaneous determination of raltegravir and raltegravir glucuronide in human plasma by liquid chromatography-tandem mass spectrometric method.

  Journal of mass spectrometry : JMS 20110201

• Initial results reported on raltegravir once-daily dosing.

  AIDS patient care and STDs 20110201

• Indications for the use of next-generation antiretroviral drugs in current clinical practice.

  Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 20110101

• Long-term safety from the raltegravir clinical development program.

  Current HIV research 20110101

• HIV-2 infection, end-stage renal disease and protease inhibitor intolerance: which salvage regimen?

  Clinical drug investigation 20110101

• Use of maraviroc-, raltegravir-, and etravirine-containing regimens in treatment-experienced patients: a case-series study.

  Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 20110101

• Interaction between antiretroviral drugs and acenocoumarol.

  Antiviral therapy 20110101

• Transmitted raltegravir resistance in an HIV-1 CRF_AG-infected patient.

  Antiviral therapy 20110101

• Added value of deep sequencing relative to population sequencing in heavily pre-treated HIV-1-infected subjects.

  PloS one 20110101

• Similar efficacy of raltegravir when used with or without a protease inhibitor in treatment-experienced patients.

  HIV clinical trials 20110101

• G140S/Q148R and N155H mutations render HIV-2 Integrase resistant to raltegravir whereas Y143C does not.

  Retrovirology 20110101

• Effect of raltegravir on the total and unintegrated proviral HIV DNA during raltegravir-based HAART.

  Antiviral therapy 20110101

• Long-lasting persistence of integrase resistance mutations in HIV-2-infected patients after raltegravir withdrawal.

  Antiviral therapy 20110101

• Successful tacrolimus treatment following renal transplant in a HIV-infected patient with raltegravir previously treated with a protease inhibitor based regimen.

  Drug metabolism and drug interactions 20110101

• Comparative effectiveness of efavirenz, protease inhibitors, and raltegravir-based regimens as first-line treatment for HIV-infected adults: a mixed treatment comparison.

  HIV clinical trials 20110101

• Implications of integrase inhibitors for HIV-infected transplantation recipients: raltegravir and dolutegravir (S/GSK 1349572).

  Bioscience trends 20110101

• Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the fetal compartment (placenta and amniotic fluid).

  Antiviral therapy 20110101

• Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results.

  HIV clinical trials 20110101

• Effect of raltegravir on the pharmacokinetics of methadone.

  Journal of clinical pharmacology 20101201

• The evaluation of catechins that contain a galloyl moiety as potential HIV-1 integrase inhibitors.

  Clinical immunology (Orlando, Fla.) 20101201

• Integrase inhibitors in the treatment of HIV-1 infection.

  The Journal of antimicrobial chemotherapy 20101201

• Dynamic escape of pre-existing raltegravir-resistant HIV-1 from raltegravir selection pressure.

  Antiviral research 20101201

• Exposure-related effects of atazanavir on the pharmacokinetics of raltegravir in HIV-1-infected patients.

  Therapeutic drug monitoring 20101201

• HIV-1 integrase sequence variability in antiretroviral naïve patients and in triple-class experienced patients subsequently treated with raltegravir.

  AIDS research and human retroviruses 20101201

• Emergence of raltegravir-resistant HIV-1 in the central nervous system.

  International journal of STD & AIDS 20101201

• Raltegravir-induced cerebellar ataxia.

  AIDS (London, England) 20101113

• HIV protease inhibitors elicit volume-sensitive Cl- current in cardiac myocytes via mitochondrial ROS.

  Journal of molecular and cellular cardiology 20101101

• Severe raltegravir-associated rhabdomyolysis: a case report and review of the literature.

  International journal of STD & AIDS 20101101

• First-line raltegravir. No evidence of comparative effectiveness.

  Prescrire international 20101101

• Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy.

  AIDS (London, England) 20101023

• Effect of raltegravir resistance mutations in HIV-1 integrase on viral fitness.

  Journal of acquired immune deficiency syndromes (1999) 20101001

• Design of a series of bicyclic HIV-1 integrase inhibitors. Part 1: selection of the scaffold.

  Bioorganic & medicinal chemistry letters 20101001

• Characterization of integrase region polymorphisms in HIV type 1 CRF06_cpx viruses in treatment-naive patients in Estonia.

  AIDS research and human retroviruses 20101001

• Physical trapping of HIV-1 synaptic complex by different structural classes of integrase strand transfer inhibitors.

  Biochemistry 20100928

• Time course of total HIV-1 DNA and 2-long-terminal repeat circles in patients with controlled plasma viremia switching to a raltegravir-containing regimen.

  AIDS (London, England) 20100924

• High neonatal concentrations of raltegravir following transplacental transfer in HIV-1 positive pregnant women.

  AIDS (London, England) 20100924

• HIV-1 subtype B and C integrase enzymes exhibit differential patterns of resistance to integrase inhibitors in biochemical assays.

  AIDS (London, England) 20100910

• Drug-drug interactions between raltegravir and pravastatin in healthy volunteers.

  Journal of acquired immune deficiency syndromes (1999) 20100901

• Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses.

  Journal of acquired immune deficiency syndromes (1999) 20100901

• Identification of novel mutations responsible for resistance to MK-2048, a second-generation HIV-1 integrase inhibitor.

  Journal of virology 20100901

• Rapid HIV-RNA decline following addition of raltegravir and tenofovir to ongoing highly active antiretroviral therapy in a woman presenting with high-level HIV viraemia at week 38 of pregnancy.

  The Journal of antimicrobial chemotherapy 20100901

• Long-term immunovirogical effect and tolerability of a maraviroc-containing regimen in routine clinical practice.

  Current HIV research 20100901

• Discovery of potent HIV integrase inhibitors active against raltegravir resistant viruses.

  Bioorganic & medicinal chemistry letters 20100901

• Raltegravir: a review of its pharmacokinetics, pharmacology and clinical studies.

  Expert opinion on drug metabolism & toxicology 20100901

• Novel integrase inhibitors for HIV.

  Expert opinion on investigational drugs 20100901

• [Genetic barrier to antiretroviral drug-resistance. Focus on raltegravir, the first integrase inhibitor].

  Medecine et maladies infectieuses 20100901

• Prevention of HIV protease inhibitor-induced dysregulation of hepatic lipid metabolism by raltegravir via endoplasmic reticulum stress signaling pathways.

  The Journal of pharmacology and experimental therapeutics 20100801

• The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial.

  PLoS medicine 20100801

• Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study.

  AIDS (London, England) 20100717

• Postprandial lipid effects of low-dose ritonavir vs. raltegravir in HIV-uninfected adults.

  AIDS (London, England) 20100717

• Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to first-generation integrase inhibitors, but minor fold changes to inhibitors with second-generation resistance profiles.

  Virology 20100705

• Raltegravir as functional monotherapy leads to virological failure and drug resistance in highly treatment-experienced HIV-infected patients.

  Scandinavian journal of infectious diseases 20100701

• Severe acute renal failure associated with rhabdomyolysis during treatment with raltegravir. A call for caution.

  The Journal of infection 20100701

• HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens.

  The Journal of antimicrobial chemotherapy 20100601

• Persistent prurigo nodularis responsive to initiation of combination therapy with raltegravir.

  Archives of dermatology 20100601

• Biochemical and pharmacological analyses of HIV-1 integrase flexible loop mutants resistant to raltegravir.

  Biochemistry 20100504

• Daily dosing of tacrolimus in patients treated with HIV-1 therapy containing a ritonavir-boosted protease inhibitor or raltegravir.

  The Journal of antimicrobial chemotherapy 20100501

• Clinical outcome in resistant HIV-2 infection treated with raltegravir and maraviroc.

  Antiviral research 20100501

• Raltegravir plasma concentrations in treatment-experienced patients receiving salvage regimens based on raltegravir with and without maraviroc coadministration.

  The Annals of pharmacotherapy 20100501

• [Integrase inhibitor: raltegravir also as first line therapy].

  MMW Fortschritte der Medizin 20100429

• [Raltegravir: initially as effective as standard therapy].

  MMW Fortschritte der Medizin 20100429

• Implementation of raltegravir in routine clinical practice: selection criteria for choosing this drug, virologic response rates, and characteristics of failures.

  Journal of acquired immune deficiency syndromes (1999) 20100401

• Efficacy, safety, and tolerability of etravirine with and without darunavir/ritonavir or raltegravir in treatment-experienced patients: analysis of the etravirine early access program in the United States.

  Journal of acquired immune deficiency syndromes (1999) 20100401

• HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects.

  Nature medicine 20100401

• Long-term efficacy and safety of the HIV integrase inhibitor raltegravir in patients with limited treatment options in a Phase II study.

  Journal of acquired immune deficiency syndromes (1999) 20100401

• A single-center cohort experience of raltegravir in salvage patients failing therapy.

  Journal of acquired immune deficiency syndromes (1999) 20100401

• Natural polymorphisms of integrase among HIV type 1-infected South African patients.

  AIDS research and human retroviruses 20100401

• Raltegravir penetration in the cerebrospinal fluid of HIV-positive patients.

  AIDS (London, England) 20100327

• A dynamic model of HIV integrase inhibition and drug resistance.

  Journal of molecular biology 20100326

• Raltegravir: in treatment-naive patients with HIV-1 infection.

  Drugs 20100326

• Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20100315

• Central nervous system T-cell lymphoma in acquired immunodeficiency syndrome.

  British journal of haematology 20100301

• Hepatic safety profile of raltegravir in HIV-infected patients with chronic hepatitis C.

  The Journal of antimicrobial chemotherapy 20100301

• Evolution of 2-long terminal repeat (2-LTR) episomal HIV-1 DNA in raltegravir-treated patients and in in vitro infected cells.

  The Journal of antimicrobial chemotherapy 20100301

• Genotypic/phenotypic patterns of HIV-1 integrase resistance to raltegravir.

  The Journal of antimicrobial chemotherapy 20100301

• Raltegravir: is a 400 mg once-daily dose enough?

  The Journal of antimicrobial chemotherapy 20100301

• HIV RNA suppression rates after 24 weeks of treatment with etravirine, darunavir/ritonavir and raltegravir in the etravirine early access programme.

  International journal of STD & AIDS 20100301

• Use of novel antiretroviral agents in rescue regimens: a case of early virological failure to raltegravir.

  Scandinavian journal of infectious diseases 20100301

• [Advance and perspective of antiretroviral therapy].

  Nihon rinsho. Japanese journal of clinical medicine 20100301

• Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20100215

• Quantification of raltegravir (MK0518) in human plasma by high-performance liquid chromatography with photodiode array detection.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20100201

• New therapeutic strategies for raltegravir.

  The Journal of antimicrobial chemotherapy 20100201

• Raltegravir-based HAART regimen in a patient with large B-cell lymphoma.

  The Annals of pharmacotherapy 20100201

• [The newest developments in anti-HIV-1 drugs].

  Yao xue xue bao = Acta pharmaceutica Sinica 20100201

• Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials.

  Lancet (London, England) 20100130

• A case of rhabdomiolysis associated with raltegravir use.

  AIDS (London, England) 20100128

• LCMS using a hybrid quadrupole time of flight mass spectrometer for impurity identification during process chemical development of a novel integrase inhibitor.

  Journal of pharmaceutical and biomedical analysis 20100105

• The HIV-1 integrase genotype strongly predicts raltegravir susceptibility but not viral fitness of primary virus isolates.

  AIDS (London, England) 20100102

• Strand transfer inhibitors of HIV-1 integrase: bringing IN a new era of antiretroviral therapy.

  Antiviral research 20100101

• Quantifying the HIV-1 integrase inhibitor raltegravir in female genital tract secretions using high-performance liquid chromatography with ultraviolet detection.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20100101

• Early emergence of raltegravir resistance mutations in patients receiving HAART salvage regimens.

  Journal of medical virology 20100101

• Integrase inhibitors: a novel class of antiretroviral agents.

  The Annals of pharmacotherapy 20100101

• Assessment of the pharmacokinetics of co-administered maraviroc and raltegravir.

  British journal of clinical pharmacology 20100101

• Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection.

  PloS one 20100101

• Response of a simian immunodeficiency virus (SIVmac251) to raltegravir: a basis for a new treatment for simian AIDS and an animal model for studying lentiviral persistence during antiretroviral therapy.

  Retrovirology 20100101

• Raltegravir is a potent inhibitor of XMRV, a virus implicated in prostate cancer and chronic fatigue syndrome.

  PloS one 20100101

• The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients.

  Antiviral therapy 20100101

• The HIV-1 integrase mutations Y143C/R are an alternative pathway for resistance to Raltegravir and impact the enzyme functions.

  PloS one 20100101

• Raltegravir, tenofovir, and emtricitabine in an HIV-infected patient with HCV chronic hepatitis, NNRTI intolerance and protease inhibitors-induced severe liver toxicity.

  European journal of medical research 20100101

• Expression of Nef from unintegrated HIV-1 DNA downregulates cell surface CXCR4 and CCR5 on T-lymphocytes.

  Retrovirology 20100101

• ICAAC update. Three new drugs in development, plus Isentress with Reyataz.

  Positively aware : the monthly journal of the Test Positive Aware Network 20100101

• Use of newer antiretroviral agents, darunavir and etravirine with or without raltegravir, in pregnancy: a report of two cases.

  Antiviral therapy 20100101

• An examination of drug-drug interactions with raltegravir.

  HIV clinician 20100101

• From bench to clinic: accessing promising investigational medications for patients with HIV infection in an urban family health center.

  Journal of the American Board of Family Medicine : JABFM 20100101

• Simplification from protease inhibitors to once- or twice-daily raltegravir: the ODIS trial.

  HIV clinical trials 20100101

• Raltegravir and unboosted atazanavir dual therapy in virologically suppressed antiretroviral treatment-experienced HIV patients.

  Antiviral therapy 20100101

• Polymorphisms of HIV-2 integrase and selection of resistance to raltegravir.

  Retrovirology 20100101

• A pilot study of abacavir/lamivudine and raltegravir in antiretroviral-naïve HIV-1-infected patients: 48-week results of the SHIELD trial.

  HIV clinical trials 20100101

• Impact on health-related quality of life of a switch from enfuvirtide to raltegravir among multidrug-resistant HIV-1-infected patients: a randomized open-label trial (EASIER-ANRS 138).

  HIV clinical trials 20100101

• Pharmacokinetics and safety of twice-daily atazanavir 300 mg and raltegravir 400 mg in healthy individuals.

  Antiviral therapy 20100101

• Oral pre-exposure prophylaxis by anti-retrovirals raltegravir and maraviroc protects against HIV-1 vaginal transmission in a humanized mouse model.

  PloS one 20100101

• [Raltegravir is the first HIV integrase inhibitor as part of antiretroviral treatment regimens].

  Terapevticheskii arkhiv 20100101

• Switch from enfuvirtide to raltegravir in virologically suppressed HIV-1 infected patients: effects on level of residual viremia and quality of life.

  Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 20091201

• Validation of an electrospray ionization LC-MS/MS method for quantitative analysis of raltegravir, etravirine, and 9 other antiretroviral agents in human plasma samples.

  Therapeutic drug monitoring 20091201

• A new drug combination therapy for treatment-naive patients with HIV-1 infection, consisting of raltegravir, emtricitabine and tenofovir disoproxil fumarate.

  Expert opinion on pharmacotherapy 20091201

• The SWITCHMRK studies: substitution of lopinavir/ritonavir with raltegravir in HIV-positive individuals.

  Expert review of anti-infective therapy 20091201

• Raltegravir, etravirine and r-darunavir combination in adolescents with multidrug-resistant virus.

  AIDS (London, England) 20091113

• [Features and the method of application of a CCR5 antagonist, a new integrase inhibitor].

  Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 20091110

• [Status of anti-HIV drug development and an overview of combined chemotherapy].

  Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 20091110

• A combined genotypic and phenotypic human immunodeficiency virus type 1 recombinant virus assay for the reverse transcriptase and integrase genes.

  Journal of virological methods 20091101

• Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infection.

  Journal of acquired immune deficiency syndromes (1999) 20091101

• Raltegravir has no residual antiviral activity in vivo against HIV-1 with resistance-associated mutations to this drug.

  The Journal of antimicrobial chemotherapy 20091101

• Lack of specificity for the analysis of raltegravir using online sample clean-up liquid chromatography-electrospray tandem mass spectrometry.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20091101

• High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20091101

• Maraviroc and raltegravir.

  British journal of clinical pharmacology 20091101

• The dynamics of appearance and disappearance of HIV-1 integrase mutations during and after withdrawal of raltegravir therapy.

  AIDS (London, England) 20091023

• Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: a randomized open-label trial.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20091015

• Mutation N155H in HIV-2 integrase confers high phenotypic resistance to raltegravir and impairs replication capacity.

  Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 20091001

• Lack of interaction between raltegravir and cyclosporin in an HIV-infected liver transplant recipient.

  The Journal of antimicrobial chemotherapy 20091001

• The effect of raltegravir on the glucuronidation of lamotrigine.

  Journal of clinical pharmacology 20091001

• Raltegravir: a new choice in HIV and new chances for research.

  Lancet (London, England) 20090905

• Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial.

  Lancet (London, England) 20090905

• Induced-fit docking approach provides insight into the binding mode and mechanism of action of HIV-1 integrase inhibitors.

  ChemMedChem 20090901

• Acute onset insomnia associated with the initiation of raltegravir: a report of two cases and literature review.

  AIDS patient care and STDs 20090901

• FDA notifications. FDA approves raltegravir for HIV-1 treatment-naive patients.

  AIDS alert 20090901

• A cascade approach to cyclic aminonitrones: reaction discovery, mechanism, and scope.

  Organic letters 20090806

• Virologic outcomes of changing enfuvirtide to raltegravir in HIV-1 patients well controlled on an enfuvirtide based regimen: 24-week results of the CHEER study.

  Journal of acquired immune deficiency syndromes (1999) 20090801

• Safety and efficacy of raltegravir in HIV-infected transplant patients cotreated with immunosuppressive drugs.

  American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 20090801

• N-(4-Fluorobenzyl)-3-hydroxy-9,9-dimethyl-4-oxo-6,7,8,9-tetrahydro-4H-pyrazino[1,2-a]pyrimidine-2-carboxamides a novel class of potent HIV-1 integrase inhibitors.

  Bioorganic & medicinal chemistry letters 20090801

• Dynamics of raltegravir resistance profile in an HIV type 2-infected patient.

  AIDS research and human retroviruses 20090801

• Raltegravir as effective as efavirenz in 144-week data.

  AIDS patient care and STDs 20090801

• FDA notifications. Raltegravir indication extended for treatment-naive patients.

  AIDS alert 20090801

• Early virologic suppression with three-class experienced patients: 24-week effectiveness in the darunavir outcomes study.

  AIDS (London, England) 20090731

• Evolution of raltegravir resistance during therapy.

  The Journal of antimicrobial chemotherapy 20090701

• Cost-effectiveness analysis of raltegravir in treatment-experienced HIV type 1-infected patients in Spain.

  AIDS research and human retroviruses 20090701

• Switch from enfuvirtide to raltegravir in patients with undetectable viral load: efficacy and safety at 24 weeks in a Montreal cohort.

  Journal of acquired immune deficiency syndromes (1999) 20090701

• Pharmacokinetics of raltegravir in individuals with UGT1A1 polymorphisms.

  Clinical pharmacology and therapeutics 20090601

• Virological and immunological response in HIV-1-infected patients with multiple treatment failures receiving raltegravir and optimized background therapy, ANRS CO3 Aquitaine Cohort.

  The Journal of antimicrobial chemotherapy 20090601

• Raltegravir: a review of its use in the management of HIV infection in treatment-experienced patients.

  Drugs 20090529

• Treatment of HIV infection with raltegravir.

  Expert opinion on pharmacotherapy 20090501

• [Medication change due to side effects or possible long-term complications. Side effect management with vision].

  MMW Fortschritte der Medizin 20090430

• [New antiretroviral drug classes in HIV therapy].

  MMW Fortschritte der Medizin 20090430

• Etravirine-raltegravir, a marked interaction in HIV-1-infected patients: about four cases.

  AIDS (London, England) 20090427

• Quantitative prediction of human clearance guiding the development of Raltegravir (MK-0518, isentress) and related HIV integrase inhibitors.

  Drug metabolism and disposition: the biological fate of chemicals 20090401

• Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients.

  The Journal of antimicrobial chemotherapy 20090401

• Raltegravir: the first HIV type 1 integrase inhibitor.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20090401

• Simultaneous determination of maraviroc and raltegravir in human plasma by HPLC-UV.

  IUBMB life 20090401

• FDA notifications. FDA grants approval for raltegravir.

  AIDS alert 20090401

• CROI 2009: a few key presentations on antiretroviral therapy.

  The AIDS reader 20090401

• Select updates from the 16th CROI: treatment-related cardiovascular risk, pharmacokinetic issues, and interleukin-2 use.

  The AIDS reader 20090401

• Report from the 16th Conference on Retroviruses and Opportunistic Infections. SWITCHMRK: an avoidable raltegravir disaster.

  Journal watch. AIDS clinical care 20090401

• A paediatric case of acute liver failure associated with efavirenz-based highly active antiretroviral therapy and effective use of raltegravir in combination antiretroviral treatment after liver transplantation.

  The Journal of antimicrobial chemotherapy 20090301

• Two studies show Kaletra and Isentress similarly suppress HIV, yet have different side effects.

  Project Inform perspective 20090301

• Isentress equal to Sustiva in first line therapy.

  Project Inform perspective 20090301

• Quantification of the HIV-integrase inhibitor raltegravir and detection of its main metabolite in human plasma, dried blood spots and peripheral blood mononuclear cell lysate by means of high-performance liquid chromatography tandem mass spectrometry.

  Journal of pharmaceutical and biomedical analysis 20090220

• Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies.

  AIDS (London, England) 20090220

• Effects of omeprazole on plasma levels of raltegravir.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20090215

• Is dual therapy with raltegravir and protease inhibitors a feasible option in rescue strategy in HIV-1 infection?

  Journal of acquired immune deficiency syndromes (1999) 20090201

• Raltegravir and etravirine are active against HIV type 1 group O.

  AIDS research and human retroviruses 20090201

• [Raltegravir as first integrase inhibitor in an HIV-infection].

  Nederlands tijdschrift voor geneeskunde 20090131

• Implications of HIV-1 M group polymorphisms on integrase inhibitor efficacy and resistance: genetic and structural in silico analyses.

  Biochemistry 20090113

• Emerging pharmacology: inhibitors of human immunodeficiency virus integration.

  Annual review of pharmacology and toxicology 20090101

• Raltegravir, elvitegravir, and metoogravir: the birth of 'me-too' HIV-1 integrase inhibitors.

  Retrovirology 20090101

• Raltegravir with unboosted atazanavir 300 mg twice daily in antiretroviral treatment-experienced participants.

  Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 20090101

• Genetic barriers for integrase inhibitor drug resistance in HIV type-1 B and CRF02_AG subtypes.

  Antiviral therapy 20090101

• Analysis of a switch from enfuvirtide to raltegravir in patients with undetectable viral load: efficacy and quality of life at 24 weeks.

  Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 20090101

• HIV dynamics and integrase inhibitors.

  Antiviral chemistry & chemotherapy 20090101

• Constraints on the dominant mechanism for HIV viral dynamics in patients on raltegravir.

  Antiviral therapy 20090101

• New hexahydrodiazocino-naphthyridine triones as HIV-1 integrase inhibitors: WO2008048538 A1.

  Expert opinion on therapeutic patents 20090101

• HIV-1 IN alternative molecular recognition of DNA induced by raltegravir resistance mutations.

  Journal of molecular recognition : JMR 20090101

• Anti-HIV agents. Atazanavir and raltegravir--an interesting combination.

  TreatmentUpdate 20090101

• Raltegravir cerebrospinal fluid concentrations in HIV-1 infection.

  PloS one 20090101

• Cost-effectiveness of raltegravir in antiretroviral treatment-experienced HIV-1-infected patients in Switzerland.

  HIV clinical trials 20090101

• Comparative biochemical analysis of HIV-1 subtype B and C integrase enzymes.

  Retrovirology 20090101

• Raltegravir: molecular basis of its mechanism of action.

  European journal of medical research 20090101

• Drug-drug interactions with raltegravir.

  European journal of medical research 20090101

• Raltegravir in treatment naive patients.

  European journal of medical research 20090101

• Raltegravir use in special populations.

  European journal of medical research 20090101

• HIV resistance to raltegravir.

  European journal of medical research 20090101

• Efficacy and safety of an NRTI-sparing dual regimen of raltegravir and ritonavir-boosted protease inhibitor in a triple antiretroviral class-experienced population.

  HIV clinical trials 20090101

• [Desensitization to tipranavir caused by toxicodermia].

  Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 20090101

• Efficacy and safety of switching from enfuvirtide to raltegravir in patients with virological suppression.

  HIV clinical trials 20090101

• An HPLC-PDA method for the simultaneous quantification of the HIV integrase inhibitor raltegravir, the new nonnucleoside reverse transcriptase inhibitor etravirine, and 11 other antiretroviral agents in the plasma of HIV-infected patients.

  Therapeutic drug monitoring 20081201

• Report from the 2008 joint ICAAC/IDSA meeting. Raltegravir vs. efavirenz in treatment-naive patients.

  AIDS clinical care 20081201

• Report from the 2008 joint ICAAC/IDSA meeting. More on raltegravir: resistance and mechanisms of action.

  AIDS clinical care 20081201

• Raltegravir for postexposure prophylaxis following occupational exposure to HIV.

  AIDS (London, England) 20081130

• Elevated alkaline phosphatase with raltegravir in a treatment experienced HIV patient.

  AIDS (London, England) 20081112

• An accurate and precise high-performance liquid chromatography method for the rapid quantification of the novel HIV integrase inhibitor raltegravir in human blood plasma after solid phase extraction.

  Analytica chimica acta 20081103

• HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro.

  The Journal of antimicrobial chemotherapy 20081101

• Darunavir-etravirine-raltegravir as salvage combination therapy in a heavily pretreated HIV-infected patient.

  AIDS patient care and STDs 20081101

• Raltegravir phase III study data released.

  AIDS patient care and STDs 20081101

• Trial will evaluate a once-daily dose of raltegravir.

  AIDS patient care and STDs 20081101

• Antiretroviral treatment update from the 17th International AIDS Conference.

  The AIDS reader 20081101

• [Raltegravir: the first HIV integrase inhibitor. Introduction].

  Enfermedades infecciosas y microbiologia clinica 20081101

• [How proviral DNA is integrated into the host cell DNA and how this process can be inhibited].

  Enfermedades infecciosas y microbiologia clinica 20081101

• [Potential of integrase inhibitors to deplete HIV reservoirs or prevent their replenishment].

  Enfermedades infecciosas y microbiologia clinica 20081101

• [Pharmacokinetics and interactions of raltegravir].

  Enfermedades infecciosas y microbiologia clinica 20081101

• [Efficacy of raltegravir: from healthy volunteers to phase III trials].

  Enfermedades infecciosas y microbiologia clinica 20081101

• [Secondary effects associated with raltegravir].

  Enfermedades infecciosas y microbiologia clinica 20081101

• [Resistance to integrase inhibitors].

  Enfermedades infecciosas y microbiologia clinica 20081101

• [Role of the new molecules in antiretroviral therapy. Position of raltegravir].

  Enfermedades infecciosas y microbiologia clinica 20081101

• Drug resistance profiles for the HIV integrase gene in patients failing raltegravir salvage therapy.

  HIV medicine 20081001

• Selection of the Q148R integrase inhibitor resistance mutation in a failing raltegravir containing regimen.

  AIDS (London, England) 20081001

• Discovery of 3-acetyl-4-hydroxy-2-pyranone derivatives and their difluoridoborate complexes as a novel class of HIV-1 integrase inhibitors.

  Bioorganic & medicinal chemistry 20081001

• [New CCR5 inhibitor antiretroviral drugs and integrase inhibitors].

  Revista clinica espanola 20081001

• Raltegravir: the first HIV integrase inhibitor.

  Clinical therapeutics 20081001

• [Darunavir in patients with advanced HIV and multiresistance. The POWER, DUET and BENCHMRK studies].

  Enfermedades infecciosas y microbiologia clinica 20081001

• Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection.

  Journal of medicinal chemistry 20080925

• Exacerbation of depression associated with starting raltegravir: a report of four cases.

  AIDS (London, England) 20080912

• Clade-specific HIV-1 integrase polymorphisms do not reduce raltegravir and elvitegravir phenotypic susceptibility.

  AIDS (London, England) 20080912

• Comparison of raltegravir and elvitegravir on HIV-1 integrase catalytic reactions and on a series of drug-resistant integrase mutants.

  Biochemistry 20080909

• Raltegravir: the first in a new class of integrase inhibitors for the treatment of HIV.

  Expert review of anti-infective therapy 20080801

• Raltegravir, an HIV-1 integrase inhibitor for HIV infection.

  Current opinion in investigational drugs (London, England : 2000) 20080801

• A conventional LC-MS method developed for the determination of plasma raltegravir concentrations.

  Biological & pharmaceutical bulletin 20080801

• Raltegravir with optimized background therapy for resistant HIV-1 infection.

  The New England journal of medicine 20080724

• Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.

  The New England journal of medicine 20080724

• Severe rhabdomyolysis associated with raltegravir use.

  AIDS (London, England) 20080711

• Atazanavir modestly increases plasma levels of raltegravir in healthy subjects.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20080701

• New treatment options for HIV salvage patients: an overview of second generation PIs, NNRTIs, integrase inhibitors and CCR5 antagonists.

  The Journal of infection 20080701

• New drugs08, part 2.

  Nursing 20080701

• Integrase inhibitors for the treatment of HIV infection.

  Current opinion in drug discovery & development 20080701

• Outcomes of multidrug-resistant patients switched from enfuvirtide to raltegravir within a virologically suppressive regimen.

  AIDS (London, England) 20080619

• Raltegravir thorough QT/QTc study: a single supratherapeutic dose of raltegravir does not prolong the QTcF interval.

  Journal of clinical pharmacology 20080601

• Integrase inhibitors: a clinical review of raltegravir and elvitegravir.

  Journal of HIV therapy 20080601

• Raltegravir treatment response in an HIV-2 infected patient: a case report.

  AIDS (London, England) 20080531

• A sensitive HPLC-MS-MS method for the determination of raltegravir in human plasma.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20080515

• Quantification of the HIV-integrase inhibitor raltegravir (MK-0518) in human plasma by high-performance liquid chromatography with fluorescence detection.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20080515

• Successful rescue therapy with Raltegravir (MK-0518) and Etravirine (TMC125) in an hiv-infected patient failing all four classes of antiretroviral drugs.

  AIDS patient care and STDs 20080501

• Raltegravir: an integrase inhibitor for HIV-1.

  Expert opinion on investigational drugs 20080301

• [New drugs for HIV infection].

  Revue de l'infirmiere 20080301

• Safe use of raltegravir and sirolimus in an HIV-infected patient with renal impairment after orthotopic liver transplantation.

  AIDS (London, England) 20080219

• Tricyclic HIV integrase inhibitors: potent and orally bioavailable C5-aza analogs.

  Bioorganic & medicinal chemistry letters 20080215

• Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.

  Clinical pharmacology and therapeutics 20080201

• Lack of a pharmacokinetic effect of raltegravir on midazolam: in vitro/in vivo correlation.

  Journal of clinical pharmacology 20080201

• [New therapeutic options in protracted HIV-infected patients with virological failure].

  Medicina clinica 20080126

• Two new drugs for HIV infection.

  The Medical letter on drugs and therapeutics 20080114

• Raltegravir.

  Drugs 20080101

• Raltegravir (MK-0518): a novel integrase inhibitor for the treatment of HIV infection.

  Expert opinion on investigational drugs 20080101

• Integrase inhibitors: a new treatment option for patients with human immunodeficiency virus infection.

  Pharmacotherapy 20080101

• New drugs: doripenem, raltegravir, and ixabepilone.

  Journal of the American Pharmacists Association : JAPhA 20080101

• The discovery of raltegravir, an integrase inhibitor for the treatment of HIV infection.

  Progress in medicinal chemistry 20080101

• Highlights of the 15th Conference on Retroviruses and Opportunistic Infections. Advances in antiretroviral therapy.

  Topics in HIV medicine : a publication of the International AIDS Society, USA 20080101

• Emerging therapies for hepatitis C and HIV in drug abusers: drugs and strategies.

  Journal of addictive diseases 20080101

• Comparing two integrase inhibitors. The first head-to-head study comparing raltegravir and elvitegravir.

  Positively aware : the monthly journal of the Test Positive Aware Network 20080101

• Raltegravir susceptibility and fitness progression of HIV type-1 integrase in patients on long-term antiretroviral therapy.

  Antiviral therapy 20080101

• No residual activity of raltegravir after development of 148 complex mutations in vivo.

  Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 20080101

• Raltegravir (MK-0518): an integrase inhibitor for the treatment of HIV-1.

  Drugs of today (Barcelona, Spain : 1998) 20071201

• Raltegravir, a new HIV integrase inhibitor.

  AIDS clinical care 20071201

• FDA notifications. Accelerated approval for raltegravir tablets.

  AIDS alert 20071201

• Substituted 2-pyrrolinone inhibitors of HIV-1 integrase.

  Bioorganic & medicinal chemistry letters 20071115

• Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase.

  AIDS (London, England) 20071112

• [Raltegravir an integrase inhibitor--a great leap forward within reach].

  Medizinische Monatsschrift fur Pharmazeuten 20071101

• FDA approves raltegravir tablets.

  AIDS patient care and STDs 20071101

• Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study.

  Journal of acquired immune deficiency syndromes (1999) 20071001

• Determination of the HIV integrase inhibitor, MK-0518 (raltegravir), in human plasma using 96-well liquid-liquid extraction and HPLC-MS/MS.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070915

• Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme.

  Drug metabolism and disposition: the biological fate of chemicals 20070901

• Studies of metabolism and disposition of potent human immunodeficiency virus (HIV) integrase inhibitors using 19F-NMR spectroscopy.

  Xenobiotica; the fate of foreign compounds in biological systems 20070901

• 48-week data on raltegravir in naive patients.

  AIDS patient care and STDs 20070901

• Approval recommended for raltegravir in experienced patients.

  AIDS patient care and STDs 20070901

• Pivotal moments in HIV treatment: the 14th CROI.

  The AIDS reader 20070501

• Advances in HIV therapeutics: the 14th CROI.

  The AIDS reader 20070501

• Raltegravir: a new antiretroviral class for salvage therapy.

  Lancet (London, England) 20070414

• Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial.

  Lancet (London, England) 20070414

• Researchers buoyed by novel HIV drugs: will expand drug arsenal against resistant virus.

  JAMA 20070411

• New drugs offer options.

  The AIDS reader 20070401

• Raltegravir demonstrates potency.

  AIDS patient care and STDs 20070401

• Anti-HIV agents. New drugs, new hope, old lessons.

  TreatmentUpdate 20070201

• Anti-HIV agents. Integrase inhibitor raltegravir makes its mark.

  TreatmentUpdate 20070201

• Anti-HIV agents. Raltegravir--other issues.

  TreatmentUpdate 20070201

• Expanded access drug profile: raltegravir (RAL, MK-0518).

  The Hopkins HIV report : a bimonthly newsletter for healthcare providers 20070101

• Anti-HIV agents. New drugs--hope and a degree of caution.

  TreatmentUpdate 20070101

• Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals.

  Journal of acquired immune deficiency syndromes (1999) 20061215

• Fuzeon combination highly effective.

  AIDS patient care and STDs 20061201

• Meeting report. Report from ICAAC.

  AIDS clinical care 20061201

• XVI International AIDS Conference: Part 2.

  The AIDS reader 20061101

• AIDS 2006 - XVI International Conference. Time to deliver.

  IDrugs : the investigational drugs journal 20061001

• The latest in antiretroviral therapy.

  Drug news & perspectives 20061001

• The clinical pharmacology of antiretrovirals in development.

  Expert opinion on drug metabolism & toxicology 20060601

• Retrovirus meeting. Novel attacks on HIV move closer to reality.

  Science (New York, N.Y.) 20060217

• MK-0518 and GS-9137: two promising integrase inhibitors in the pipeline.

  BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation 20060101

• Integrase inhibitor MK-0518: Merck opens expanded-access program.

  AIDS treatment news 20060101

• Anti-HIV agents. Some drug interactions with Merck's integrase inhibitor.

  TreatmentUpdate 20060101

• Anti-HIV agents. Merck integrase inhibitor.

  TreatmentUpdate 20060101